Spyre Therapeutics Inc (SYRE) Stock Price, Quote & News

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and S...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 5940

Website: www.spyre.com

Address:

221 Crescent Street, Building 23 Suite 105, Waltham, United States

Iightning Dec. 5 at 4:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $35C Entry: 2.90 Exit: 5.72 Return: +97.11% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:34 PM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $35C Entry: 2.90 Exit: 5.72 Return: +97.11% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 6:14 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $30C Entry: 2.95 Exit: 5.21 Return: +76.47% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Pika_Capital Dec. 4 at 1:44 AM

$ORKA $APGE $SYRE All 3 doubled pretty much. What a year for Pika. Ordered RTX 5090 as a Christmas gift 😂 time for upgrade baby.

0 · Reply

CocaKolla Dec. 3 at 11:25 PM

$SYRE looks good here

0 · Reply

Iightning Dec. 3 at 10:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $22.5C Entry: 3.20 Exit: 5.01 Return: +56.41% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HodlMaBeer Dec. 2 at 2:53 PM

$SYRE amazing pick up this was at 15

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:14 PM

$SXT $SYF $SYM $SYRE $TAC Proven Accuracy

0 · Reply

Iightning Dec. 2 at 12:31 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $SYRE **Contract:** Dec 19 $30C **Entry:** 2.92 **Exit:** 5.38 **Return:** **+83.77% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

JarvisFlow Dec. 1 at 1:17 PM

Jones Trading updates rating for Spyre Therapeutics ( $SYRE ) to Buy, target set at 64.

0 · Reply

Spyre Therapeutics Announces Grants of Inducement Awards

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Oct 24, 2025, 8:00 AM EDT - 5 weeks ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Oct 15, 2025, 4:15 PM EDT - 7 weeks ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Oct 13, 2025, 9:07 PM EDT - 7 weeks ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Oct 13, 2025, 4:01 PM EDT - 7 weeks ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Oct 5, 2025, 9:00 AM EDT - 2 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Sep 18, 2025, 10:34 PM EDT - 2 months ago

Intelligent Development Could Make Spyre Therapeutics Best In Show

Sep 8, 2025, 4:05 PM EDT - 3 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Aug 6, 2025, 9:45 AM EDT - 4 months ago

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

Aug 5, 2025, 4:02 PM EDT - 4 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 18, 2025, 2:58 PM EDT - 6 months ago

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Jun 17, 2025, 7:30 AM EDT - 6 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Jun 16, 2025, 4:05 PM EDT - 6 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

May 28, 2025, 8:30 AM EDT - 6 months ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 8, 2025, 4:05 PM EDT - 7 months ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 8:00 AM EDT - 7 months ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 4, 2025, 4:51 AM EST - 9 months ago

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Feb 27, 2025, 4:05 PM EST - 10 months ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 10 months ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 10 months ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Jan 13, 2025, 8:00 AM EST - 11 months ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Dec 18, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 4, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 2, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Dec 2, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 1, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Nov 29, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Nov 28, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Nov 27, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Nov 25, 2024, 5:11 PM EST - 1 year ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Nov 24, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Nov 21, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Nov 20, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Nov 18, 2024, 9:18 PM EST - 1 year ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Nov 12, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Nov 11, 2024, 4:05 PM EST - 1 year ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Iightning Dec. 5 at 4:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $35C Entry: 2.90 Exit: 5.72 Return: +97.11% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:34 PM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $35C Entry: 2.90 Exit: 5.72 Return: +97.11% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 6:14 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $30C Entry: 2.95 Exit: 5.21 Return: +76.47% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Pika_Capital Dec. 4 at 1:44 AM

$ORKA $APGE $SYRE All 3 doubled pretty much. What a year for Pika. Ordered RTX 5090 as a Christmas gift 😂 time for upgrade baby.

0 · Reply

CocaKolla Dec. 3 at 11:25 PM

$SYRE looks good here

0 · Reply

Iightning Dec. 3 at 10:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SYRE Contract: Dec 19 $22.5C Entry: 3.20 Exit: 5.01 Return: +56.41% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HodlMaBeer Dec. 2 at 2:53 PM

$SYRE amazing pick up this was at 15

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:14 PM

$SXT $SYF $SYM $SYRE $TAC Proven Accuracy

0 · Reply

Iightning Dec. 2 at 12:31 AM

0 · Reply

JarvisFlow Dec. 1 at 1:17 PM

Jones Trading updates rating for Spyre Therapeutics ( $SYRE ) to Buy, target set at 64.

0 · Reply

Cache_Money Nov. 28 at 5:28 PM

$SYRE New play. Good targets even if there is a lot of competition.

0 · Reply

FennickTradings Nov. 28 at 11:14 AM

$SYRE give me some cvr

0 · Reply

Swing_Tradr Nov. 26 at 9:15 PM

$SYRE was called out by TradrSense Pro on 11/12 with an entry of $23.43 and it hit the TP of $28.00 on 11/25/2025. It's currently trading at $29.73 with upward momentum. Check out TradrSense Pro at: https://swingtradr.com/tradr-sense

0 · Reply

Iightning Nov. 26 at 3:23 AM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $30 Call | Enter: $1.71 Exit: $2.60 | Profit: 52.10% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:29 PM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $30 Call | Enter: $1.71 Exit: $2.60 | Profit: 52.10% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $30 Call | Enter: $1.71 Exit: $2.60 | Profit: 52.10% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 23 at 5:47 PM

$SXT $SYF $SYM $SYRE $TAC

0 · Reply

Iightning Nov. 21 at 11:38 PM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $25 Call | Enter: $2.60 Exit: $5.00 | Profit: 92.27% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 2:58 AM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $25 Call | Enter: $2.60 Exit: $5.00 | Profit: 92.27% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 12:21 AM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $25 Call | Enter: $2.60 Exit: $5.00 | Profit: 92.27% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:35 AM

1ightning® Options Trade Alert (Actionable) | Buy $SYRE Dec 19 $25 Call | Enter: $2.60 Exit: $5.00 | Profit: 92.27% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 9 at 11:11 PM

$SXI $SYF $SYK $SYRE $T

0 · Reply

Market Cap	2.20B
Revenue (ttm)	0.00
Net Income (ttm)	-208.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	938,100
Avg Vol	962,072
Day's Range	N/A - N/A
Shares Out	77.59M
Stochastic %K	91%
Beta	3.14
Analysts	Strong Sell
Price Target	$53.58